Fig. 7
From: Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Cytokine-encoded mRNA-LNP Delivery System. a Schematic representation of tumor challenge with cytokine-encoded mRNA-LNP systems. b Tumor volume and survival rate in the B16F10 tumor model treated with IL-12-encoded mRNA-LNPs. The IL-12-alb-lum mRNA-LNP formulation demonstrated effective tumor suppression efficacy. a–b: Reproduced from a previous report [106] with permission from Springer Nature). c Tumor volume measured for IL-23, IL-36γ, and OX40L-encoded mRNA-LNPs, showing anticancer effects in the MC38-R tumor model. d Tumor volume suppression due to the abscopal effect of IL-23, IL-36γ, and OX40L-encoded mRNA-LNPs. c–d: Reproduced from a previous report [111] with permission from American Association for the Advancement of Science). e Schematic of IL-12, IL-27, and GM-CSF-encoded mRNA-LNP systems. f Cytokine concentrations following treatment with IL-27, IL-12, or GM-CSF mRNA-loaded MC3-LNPs or DAL4-LNPs. g Tumor size measured in the B16F10 murine model treated with DAL4-LNP-encapsulated mRNA. h Survival rate in the B16F10 murine model treated with mRNA-loaded DAL4-LNPs. e–h: Reproduced from a previous report [7] with permission from Elsevier)